Early onset of natalizumab-related progressive multifocal leukoencephalopathy

Saved in:
Bibliographic Details
Published in:Multiple sclerosis 2011-11, Vol.17 (11), p.1397-1398
Main Authors: Damasceno, A, von Glehn, F, Martinez, ARM, Longhini, ALF, Deus-Silva, L, Brandão, CO, Santos, LMB, Damasceno, BP
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal, Humanized - adverse effects
Glatiramer Acetate
Humans
Immunologic Factors - adverse effects
Immunosuppressive Agents - administration & dosage
Leukoencephalopathy, Progressive Multifocal - chemically induced
Leukoencephalopathy, Progressive Multifocal - diagnosis
Leukoencephalopathy, Progressive Multifocal - therapy
Male
Mianserin - administration & dosage
Mianserin - analogs & derivatives
Multiple Sclerosis, Relapsing-Remitting - drug therapy
Natalizumab
Peptides - administration & dosage
Plasma Exchange
Treatment Outcome
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c363t-5b20270516b8710c6b0ad6557be92932857b5a71ce515d23d667cf8d89a325e33
cites cdi_FETCH-LOGICAL-c363t-5b20270516b8710c6b0ad6557be92932857b5a71ce515d23d667cf8d89a325e33
container_end_page 1398
container_issue 11
container_start_page 1397
container_title Multiple sclerosis
container_volume 17
creator Damasceno, A
von Glehn, F
Martinez, ARM
Longhini, ALF
Deus-Silva, L
Brandão, CO
Santos, LMB
Damasceno, BP
description
doi_str_mv 10.1177/1352458511422929
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_911160396</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1352458511422929</sage_id><sourcerecordid>2521381671</sourcerecordid><originalsourceid>FETCH-LOGICAL-c363t-5b20270516b8710c6b0ad6557be92932857b5a71ce515d23d667cf8d89a325e33</originalsourceid><addsrcrecordid>eNp1kE1PwzAMhiMEYmNw54QqLpwK-WiS5oim8SENcYFzlabu1pE2I2mRxq8n0wZISMgHW_Lj1_aL0DnB14RIeUMYpxnPOSEZpYqqAzQmmZQpVhIfxjq2021_hE5CWGGMpWT8GI0oURgzLsboaaa93SSuC9Anrk463WvbfA6tLlMPVvdQJWvvFh5CaD4gaQfbN7Uz2iYWhjcHnYH1Ulu31v1yc4qOam0DnO3zBL3ezV6mD-n8-f5xejtPDROsT3lJMZWYE1HmkmAjSqwrwbksIT7BaB4rriUxwAmvKKuEkKbOq1xpRjkwNkFXO9142vsAoS_aJhiwVnfghlAoQojATIlIXv4hV27wXTyuUFhQxrIYE4R3kPEuBA91sfZNq_2mILjYGl38NTqOXOx1h7KF6mfg29kIpDsg6AX8Lv1X8At9xISF</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>906233434</pqid></control><display><type>article</type><title>Early onset of natalizumab-related progressive multifocal leukoencephalopathy</title><source>SAGE</source><creator>Damasceno, A ; von Glehn, F ; Martinez, ARM ; Longhini, ALF ; Deus-Silva, L ; Brandão, CO ; Santos, LMB ; Damasceno, BP</creator><creatorcontrib>Damasceno, A ; von Glehn, F ; Martinez, ARM ; Longhini, ALF ; Deus-Silva, L ; Brandão, CO ; Santos, LMB ; Damasceno, BP</creatorcontrib><identifier>ISSN: 1352-4585</identifier><identifier>EISSN: 1477-0970</identifier><identifier>DOI: 10.1177/1352458511422929</identifier><identifier>PMID: 21900356</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Antibodies, Monoclonal, Humanized - adverse effects ; Glatiramer Acetate ; Humans ; Immunologic Factors - adverse effects ; Immunosuppressive Agents - administration &amp; dosage ; Leukoencephalopathy, Progressive Multifocal - chemically induced ; Leukoencephalopathy, Progressive Multifocal - diagnosis ; Leukoencephalopathy, Progressive Multifocal - therapy ; Male ; Mianserin - administration &amp; dosage ; Mianserin - analogs &amp; derivatives ; Multiple Sclerosis, Relapsing-Remitting - drug therapy ; Natalizumab ; Peptides - administration &amp; dosage ; Plasma Exchange ; Treatment Outcome ; Young Adult</subject><ispartof>Multiple sclerosis, 2011-11, Vol.17 (11), p.1397-1398</ispartof><rights>SAGE Publications 2011</rights><rights>SAGE Publications © Nov 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c363t-5b20270516b8710c6b0ad6557be92932857b5a71ce515d23d667cf8d89a325e33</citedby><cites>FETCH-LOGICAL-c363t-5b20270516b8710c6b0ad6557be92932857b5a71ce515d23d667cf8d89a325e33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924,79135</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21900356$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Damasceno, A</creatorcontrib><creatorcontrib>von Glehn, F</creatorcontrib><creatorcontrib>Martinez, ARM</creatorcontrib><creatorcontrib>Longhini, ALF</creatorcontrib><creatorcontrib>Deus-Silva, L</creatorcontrib><creatorcontrib>Brandão, CO</creatorcontrib><creatorcontrib>Santos, LMB</creatorcontrib><creatorcontrib>Damasceno, BP</creatorcontrib><title>Early onset of natalizumab-related progressive multifocal leukoencephalopathy</title><title>Multiple sclerosis</title><addtitle>Mult Scler</addtitle><subject>Antibodies, Monoclonal, Humanized - adverse effects</subject><subject>Glatiramer Acetate</subject><subject>Humans</subject><subject>Immunologic Factors - adverse effects</subject><subject>Immunosuppressive Agents - administration &amp; dosage</subject><subject>Leukoencephalopathy, Progressive Multifocal - chemically induced</subject><subject>Leukoencephalopathy, Progressive Multifocal - diagnosis</subject><subject>Leukoencephalopathy, Progressive Multifocal - therapy</subject><subject>Male</subject><subject>Mianserin - administration &amp; dosage</subject><subject>Mianserin - analogs &amp; derivatives</subject><subject>Multiple Sclerosis, Relapsing-Remitting - drug therapy</subject><subject>Natalizumab</subject><subject>Peptides - administration &amp; dosage</subject><subject>Plasma Exchange</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>1352-4585</issn><issn>1477-0970</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNp1kE1PwzAMhiMEYmNw54QqLpwK-WiS5oim8SENcYFzlabu1pE2I2mRxq8n0wZISMgHW_Lj1_aL0DnB14RIeUMYpxnPOSEZpYqqAzQmmZQpVhIfxjq2021_hE5CWGGMpWT8GI0oURgzLsboaaa93SSuC9Anrk463WvbfA6tLlMPVvdQJWvvFh5CaD4gaQfbN7Uz2iYWhjcHnYH1Ulu31v1yc4qOam0DnO3zBL3ezV6mD-n8-f5xejtPDROsT3lJMZWYE1HmkmAjSqwrwbksIT7BaB4rriUxwAmvKKuEkKbOq1xpRjkwNkFXO9142vsAoS_aJhiwVnfghlAoQojATIlIXv4hV27wXTyuUFhQxrIYE4R3kPEuBA91sfZNq_2mILjYGl38NTqOXOx1h7KF6mfg29kIpDsg6AX8Lv1X8At9xISF</recordid><startdate>20111101</startdate><enddate>20111101</enddate><creator>Damasceno, A</creator><creator>von Glehn, F</creator><creator>Martinez, ARM</creator><creator>Longhini, ALF</creator><creator>Deus-Silva, L</creator><creator>Brandão, CO</creator><creator>Santos, LMB</creator><creator>Damasceno, BP</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope></search><sort><creationdate>20111101</creationdate><title>Early onset of natalizumab-related progressive multifocal leukoencephalopathy</title><author>Damasceno, A ; von Glehn, F ; Martinez, ARM ; Longhini, ALF ; Deus-Silva, L ; Brandão, CO ; Santos, LMB ; Damasceno, BP</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c363t-5b20270516b8710c6b0ad6557be92932857b5a71ce515d23d667cf8d89a325e33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Antibodies, Monoclonal, Humanized - adverse effects</topic><topic>Glatiramer Acetate</topic><topic>Humans</topic><topic>Immunologic Factors - adverse effects</topic><topic>Immunosuppressive Agents - administration &amp; dosage</topic><topic>Leukoencephalopathy, Progressive Multifocal - chemically induced</topic><topic>Leukoencephalopathy, Progressive Multifocal - diagnosis</topic><topic>Leukoencephalopathy, Progressive Multifocal - therapy</topic><topic>Male</topic><topic>Mianserin - administration &amp; dosage</topic><topic>Mianserin - analogs &amp; derivatives</topic><topic>Multiple Sclerosis, Relapsing-Remitting - drug therapy</topic><topic>Natalizumab</topic><topic>Peptides - administration &amp; dosage</topic><topic>Plasma Exchange</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Damasceno, A</creatorcontrib><creatorcontrib>von Glehn, F</creatorcontrib><creatorcontrib>Martinez, ARM</creatorcontrib><creatorcontrib>Longhini, ALF</creatorcontrib><creatorcontrib>Deus-Silva, L</creatorcontrib><creatorcontrib>Brandão, CO</creatorcontrib><creatorcontrib>Santos, LMB</creatorcontrib><creatorcontrib>Damasceno, BP</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>Multiple sclerosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Damasceno, A</au><au>von Glehn, F</au><au>Martinez, ARM</au><au>Longhini, ALF</au><au>Deus-Silva, L</au><au>Brandão, CO</au><au>Santos, LMB</au><au>Damasceno, BP</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Early onset of natalizumab-related progressive multifocal leukoencephalopathy</atitle><jtitle>Multiple sclerosis</jtitle><addtitle>Mult Scler</addtitle><date>2011-11-01</date><risdate>2011</risdate><volume>17</volume><issue>11</issue><spage>1397</spage><epage>1398</epage><pages>1397-1398</pages><issn>1352-4585</issn><eissn>1477-0970</eissn><cop>London, England</cop><pub>SAGE Publications</pub><pmid>21900356</pmid><doi>10.1177/1352458511422929</doi><tpages>2</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1352-4585
ispartof Multiple sclerosis, 2011-11, Vol.17 (11), p.1397-1398
issn 1352-4585
1477-0970
language eng
recordid cdi_proquest_miscellaneous_911160396
source SAGE
subjects Antibodies, Monoclonal, Humanized - adverse effects
Glatiramer Acetate
Humans
Immunologic Factors - adverse effects
Immunosuppressive Agents - administration & dosage
Leukoencephalopathy, Progressive Multifocal - chemically induced
Leukoencephalopathy, Progressive Multifocal - diagnosis
Leukoencephalopathy, Progressive Multifocal - therapy
Male
Mianserin - administration & dosage
Mianserin - analogs & derivatives
Multiple Sclerosis, Relapsing-Remitting - drug therapy
Natalizumab
Peptides - administration & dosage
Plasma Exchange
Treatment Outcome
Young Adult
title Early onset of natalizumab-related progressive multifocal leukoencephalopathy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T20%3A48%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Early%20onset%20of%20natalizumab-related%20progressive%20multifocal%20leukoencephalopathy&rft.jtitle=Multiple%20sclerosis&rft.au=Damasceno,%20A&rft.date=2011-11-01&rft.volume=17&rft.issue=11&rft.spage=1397&rft.epage=1398&rft.pages=1397-1398&rft.issn=1352-4585&rft.eissn=1477-0970&rft_id=info:doi/10.1177/1352458511422929&rft_dat=%3Cproquest_cross%3E2521381671%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c363t-5b20270516b8710c6b0ad6557be92932857b5a71ce515d23d667cf8d89a325e33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=906233434&rft_id=info:pmid/21900356&rft_sage_id=10.1177_1352458511422929&rfr_iscdi=true